Despite strong evidence connecting several receptor tyrosine kinases, including the platelet-derived growth factor receptor (PDGFR), in the pathogenesis of GBM, the clinical use of receptor tyrosine kinases inhibitors for treatment of different forms of GBM has been greatly compromised by the rapid emergence of therapeutic resistance44. This evidence concerns the gene NTRK1 and glioblastoma.